CGON — CG Oncology, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1991792 ·
Last close
$78.94
Market Cap
$7.00B
52W High
$93.95
52W Low
$37.01
ADV30
1,481,862
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,604,000 -1,065,000 -63,249,000 -56,891,000 1,046,670,000 28,247,000 55,704,000
Jun 2026 1,157,000 -2,768,000 -86,401,000 -79,056,000 1,085,655,000 19,636,000 56,537,000
Mar 2026 1,083,000 -1,879,000 -66,389,000 -60,202,000 1,135,262,000 33,700,000 43,483,000
Dec 2025 2,322,000 -748,000 -48,700,000 -41,309,000 791,592,000 32,490,000 38,990,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-178,467,000
Investing CF
$-364,877,000
Financing CF
$548,356,000
CapEx
$-876,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.72
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-518,234,000
Inventory
$1,003,000
Receivables
$417,000
ST Investments
$1,008,642,000
EBIT TTM
$-252,619,000
Pretax Income TTM
$-224,375,000
Interest Exp TTM
—
Analysts
13

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,228,000
EBITDA
$-249,663,008
Free Cash Flow
$-113,709,872
Enterprise Value
$4,724,437,504
Total Cash
$1,028,278,016
Total Debt
$8,819,000
Shares Out
88,640,375
Trailing EPS
$-2.76
Book Value
$9.33
ROE
-26.4%
ROA
-17.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,040,000 -190,774,000 -160,995,000 791,592,000 38,990,000 752,602,000 -132,346,000
Dec 2024 1,139,000 -114,666,000 -88,039,000 754,797,000 21,420,000 733,377,000 -78,713,000
Dec 2023 204,000 -55,449,000 -48,607,000 199,301,000 14,511,000 184,790,000 -45,679,000
Dec 2022 191,000 -35,246,000 -35,443,000 147,747,000 22,570,000 125,177,000 -29,804,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$6,228,000
NetIncome TTM
$-224,375,000
OpCashFlow TTM
—
Assets (Latest)
$1,085,655,000
Forward EPS
$-2.92

Max Pain — expiry 2026-12-18

max pain strike: $60.00 · spot: $80.00 · call oi: 3,951 · put oi: 2,228

Peers — same industry

TickerNameMarket CapLastDaily %
IMVT Immunovant, Inc. $6.87B $33.21 —
IBRX ImmunityBio, Inc. $6.66B $6.26 —
TWST Twist Bioscience Corp $7.43B $112.00 —
KOD Kodiak Sciences Inc. $6.33B $96.80 —
KRYS Krystal Biotech, Inc. $8.85B $298.55 —

News headlines (Yahoo Finance, 1h cache)

CG Oncology's Next Stock Rally May Take Time After 'Impressive' Trial Results for Bladder Cancer Drug, RBC Says
2026-11-17 16:00 · Yahoo
Is CG Oncology (CGON) Fully Valued As Phase 3 Trial Success Lifts Its Outlook?
2026-11-17 14:14 · Yahoo
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
2026-11-16 21:28 · Yahoo
2 Cancer-Drug Developers Seeing Unusual Options Volume
2026-11-16 18:01 · Yahoo
This Biotech Stock Is Up 291% From Its IPO Price. It’s On Pace for a Record Closing High.
2026-11-16 17:37 · Yahoo
CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial
2026-11-16 17:00 · Yahoo
CG Oncology’s stock up as gene therapy gains second win in NMIBC
2026-11-16 16:03 · Yahoo
CG Oncology Reports 68% Reduction in Bladder Cancer Recurrence Risk in Phase 3 PIVOT-006 Trial
2026-11-16 16:02 · Yahoo
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
2026-11-16 13:00 · Yahoo
What CG Oncology (CGON)'s Third Quarter Earnings Means For Shareholders
2026-11-10 13:09 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-11-18 16:30:03 2026-11-18 Kalofonos Isabel Chief Commercial Officer P - Purchase 79.76 3751 299161
2026-11-18 16:30:07 2026-11-18 Kuan Arthur CEO P - Purchase 78.88 30000 2366425